Application of monomeric compounds of fruits of Chinese magnoliavine (Schisandra chinensis(Turcz.) baill. and Schisandra sphenanthera Rehd.et Wils) to preparation of medicine for preventing and treating cholestasis liver diseases

A technology for cholestasis and Schisandra chinensis, applied in the field of medicine, can solve the problems of limited content, restrict the full development and application of Schisandra chinensis, and achieve the effect of broadening the scope of application and good application prospect.

CN107569481AInactive Publication Date: 2018-01-12SUN YAT SEN UNIV
2 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2018-01-12
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses application of monomeric compounds of fruits of Chinese magnoliavine (Schisandra chinensis(Turcz.) baill. and Schisandra sphenanthera Rehd.et Wils) to preparation of medicine for preventing and treating cholestasis liver diseases. The monomeric compounds of fruits of Chinese magnoliavine refer to Schisandrin B, Schisandrin C, Schisandrol A, Schisantherrin A and Schisantherrin B. The result of the study shows that all of the five kinds of monomeric compounds can obviously reduce the content of total bile acids and direct bilirubin in blood serum in the cholestasis liverdisease state, can relieve the cholestasis symptoms, can reduce the activity of alkaline phosphatase, gamma-glutamyltransferase, aspartate transaminase and / or alanine aminotransferase in the liver, and can effectively improve the liver tissue necrosis degree. The invention discovers the condition for the first time that the five kinds of monomeric compounds of fruits of Chinese magnoliavine can beused for effectively preventing and treating the cholestasis liver diseases induced by liithocholic acid. The discovery provides the powerful technical theoretical basis for the new medicine researchand development for the cholestasis liver diseases and the clinic application of the monomeric compounds of fruits of Chinese magnoliavine; and wide application prospects are realized in the field ofcholestasis prevention and treatment.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of medicine. More specifically, it relates to the application of Schizandra monomer compounds in the preparation of drugs for preventing and treating cholestatic liver diseases. Background technique

[0002] Cholestasis refers to the pathological state of bile formation, secretion and excretion disorders caused by various reasons inside and outside the liver, bile cannot flow into the duodenum normally and enters the blood, clinically it can be manifested as itching, fatigue, dark urine and jaundice Wait. In the early asymptomatic period, only the serum alkaline phosphatase (ALP) and γ-glutamyl transferase (Gamma-glutamyl transferase, γ-GT) levels increased, and hyperbilirubinemia may appear after the disease progresses. Severe cases can lead to liver failure and even death. Hepatobiliary diseases mainly manifested by cholestasis caused by liver lesions are collectively referred to as cholestatic liver di...

Examples

Embodiment 1

[0036] Prevention and treatment of mouse intrahepatic cholestasis model caused by excessive lithocholic acid of embodiment 1

[0037] 1. Materials and instruments

[0038] (1) Main instruments:

[0039] 5417-R low-temperature high-speed centrifuge (Eppendorf, Germany); full-wavelength microplate reader (Thermo, USA); Hitachi 7020 automatic biochemical analyzer (HITACHI, Japan)

[0040] (2) Drugs and reagents:

[0041] Table 1 The source and dosage of the main reagents used in the test

[0042]

[0043]

[0044] 2. Experimental method

[0045] (1) Experimental animals

[0046] C57BL / 6 mice, male, 7-9 weeks old, were provided by the Guangdong Medical Experimental Animal Center, license number SYXK (Guangdong) 2016-0112, and normal mice were fed with maintenance feed. All mice were randomly divided into 7 groups, 7 to 9 in each group, the groups were: blank control group, LCA model group, SinB+LCA group, SinC+LCA group, SolA+LCA group, StnA+LCA group, StnB+LCA group g...

Embodiment 2

[0070] A pharmaceutical composition for preventing and treating cholestatic liver disease, which comprises one or more of Schizandrin B, Schizandrin C, Schisandrin A, Schizandrin A or Schizandrin B.

[0071] The medicine can be prepared into tablets, capsules, granules, powders, solutions or suspensions by adding auxiliary materials. Simultaneously, the dosage form of the medicine can also be made into a sustained-release agent or a controlled-release agent according to actual needs.

[0072]Wherein, the auxiliary material is one or more of fillers, binders, wetting agents, disintegrants, flavoring agents, lubricants or preservatives.

[0073] Specifically, the filler can be selected from one or more of starch, sucrose, dextrin, lactose, microcrystalline cellulose or mannitol; the wetting agent and binder can be selected from starch slurry, fiber One or more of vegan derivatives, alginate, gelatin or glycerin; the disintegrant can be selected from dry starch, sodium starch gl...